Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 12/20 | 0.47 |
| ▸ | PKN1 | Q16512 | 3/20 | 0.41 |
| ▸ | PAK4 | O96013 | 2/20 | 0.41 |
| ▸ | PAK1 | Q13153 | 3/20 | 0.39 |
| ▸ | PAK3 | O75914 | 2/20 | 0.38 |
| ▸ | PAK2 | Q13177 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | WEE1 | P30291 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16309192 | 0.91 | TNK2 (0.46) | TNK2PKN1PAK4PAK1WEE1 | |
| SCHEMBL15036057 | 0.82 | TNK2 (0.47) | TNK2PKN1PAK4PAK1WEE1 | |
| SCHEMBL15041504 | 0.81 | PKN1 (0.40) | TNK2PKN1PAK4PAK1PAK3 | |
| SCHEMBL15041507 | 0.81 | TNK2 (0.44) | TNK2PKN1PAK4PAK1PAK3 | |
| SCHEMBL15036026 | 0.81 | TNK2 (0.44) | TNK2PKN1PAK4PAK1PAK3 | |
| SCHEMBL15041669 | 0.76 | PTK2 (0.43) | TNK2PTK2 | |
| SCHEMBL15041668 | 0.76 | CDK4 (0.37) | TNK2PKN1PAK4 | |
| SCHEMBL15035995 | 0.76 | TNK2 (0.42) | TNK2PKN1PAK4PAK1PAK3 | |
| SCHEMBL14682005 | 0.75 | TNK2 (0.48) | TNK2PKN1PAK4PAK1PTK2 | |
| SCHEMBL13553839 | 0.75 | PAK1 (0.42) | TNK2PKN1PAK4PAK1PAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912203-B2 | 6-(sulfonylaryl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders | AFRAXIS HOLDINGS, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-20130252966-A1 | 6-(SULFONYLARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130252966-A1 | 6-(SULFONYLARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252966-A1 | 6-(SULFONYLARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | PAK2, PAK6, PAK3 | TNK2 14/4885PKN1 534/4885PAK4 5/4885 |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | TNK2 7/4885PKN1 326/4885PAK4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.